ArticleNaunyn-Schmiedeberg's archives of pharmacology2026
Broad-spectrum antiviral potential of vitexin and isovitexin from Jatropha integerrima: in vitro cytoprotective effects and in silico insights.
Article in Naunyn-Schmiedeberg's archives of pharmacology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
2 citing papers in PubMed.
- Combination of Melittin andInternational journal of molecular sciences · 2026Article
- Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
The ongoing emergence of viral infections underscores the need for new antiviral agents with broad-spectrum potential, particularly those derived from natural products. In this study, leaf and flower extracts of Jatropha integerrima, along with two isolated flavone C-glycosides, vitexin, and isovitexin, were evaluated for their antiviral potential against a panel of human DNA and RNA viruses, including hepatitis A virus, herpes simplex virus types 1 and 2, adenovirus, Coxsackievirus B4, and rotavirus A. Cytotoxicity and virus-induced cytopathic effects were assessed in Vero cells using an MTT-based assay, allowing estimation of 50% cytotoxic concentrations (CC₅₀), 50% inhibitory concentrations (IC₅₀), and selectivity indices (SI). The extracts and isolated compounds exhibited variable degrees of cytoprotective effects in infected cells, with vitexin and isovitexin showing favorable selectivity profiles against selected viruses. Morphological observations supported the MTT findings, indicating partial preservation of cell integrity under certain treatment conditions. To explore potential molecular interactions relevant to coronavirus infection, in silico molecular docking was performed against five SARS-CoV-2-related targets, including Mpro, spike glycoprotein, nucleocapsid phosphoprotein, the ACE2 receptor-RBD complex, and nsp10. Both flavonoids generated favorable binding poses within the defined binding regions of the selected proteins, with predicted binding energies suggesting potential structural compatibility with these targets. These computational findings are presented as hypothesis-generating insights and do not constitute experimental evidence of antiviral efficacy against SARS-CoV-2. Overall, the findings suggest that vitexin and isovitexin possess in vitro cytoprotective effects in virus-infected cells and exhibit predicted interactions with viral targets in silico. However, given the indirect nature of the antiviral assays and the absence of direct viral replication measurements, the results should be interpreted cautiously. Further studies employing direct virological endpoints are required to validate the antiviral potential of these compounds and to clarify their mechanisms of action.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.